UK Study Matches Mesothelioma Treatments to Genetic Profile

University of Leicester researchers soon will open the first molecularly stratified clinical trial for malignant mesothelioma with the hope of moving the future of treatment toward more personalization. The phase II trial in the United Kingdom is designed to match therapy with a patient’s specific genetic profile. “We’re trying to bring the right drug to the right patient at the right time,” Professor Dean Fennell, chair of thoracic medical oncology at Leicester and chief trial investigator, told Asbestos.com. “We need to find different treatments that work for different people. This is a step in that direction.” The British Lung Foundation funded the clinical trial, which is expected to start early in 2019 and conclude by 2022. “The problem with mesothelioma has been the one-size-fits-all approach to drug development, and it hasn’t worked,” Fennell said. “We are now entering the era of personalized treatment for many cancers, including this one.” Mesothelioma Treatment Advances Overdue A combination of chemotherapy with cisplatin and pemetrexed is still the only FDA-approved treatment for unresectable mesothelioma. The treatment hasn’t changed in 14 years, contributing to the typically dismal prognosis. Various experimental drugs — particularly immunotherapy drugs — have shown great effectiveness in select individuals but little effectiveness for the majority of patients. The lack of consis...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Mesothelin is a cell surface protein that is an excellent target for immunotherapy because of its limited expression on normal tissues and its high expression on many cancers, including mesothelioma, cholangiocarcinoma, pancreatic, ovarian, lung, stomach, bile duct, and triple-negative breast cancer.Researchers at the National Cancer Institute ’s (NCI)Laboratory of Molecular Biology have isolated two anti-mesothelin single domain antibodies (also known as nanobodies), A101 and G8. These antibodies have been isolated from newly developed camel single domain (VHH) libraries by phage display and have been used to shown ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Dr. James Cusack at Massachusetts General Hospital has begun using a novel imaging system for patients with peritoneal mesothelioma that could better identify tumor cells during surgery, reducing the chance of recurrence. Cusack, an associate professor of surgery at the Harvard University Medical School, is also studying the molecular imaging technology with select cases of appendiceal, ovarian and gastrointestinal cancers. The single-center clinical trial, which started April 3, aims to determine safety and efficacy of the procedure for peritoneum metastases, according to Cusack. The Lumicell System already has been studi...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This study is an important step forward in highlighting C1q as a new prognostic candidate biomarker for a range of carcinomas. Methods Oncomine Database Analysis The expression levels of C1QA, C1QB, and C1QC genes in various carcinomas were analyzed using Oncomine (www.oncomine.org), a cancer microarray database and web-based data mining platform from genome-wide expression analyses (22, 23). We compared the differences in mRNA level between normal tissue and carcinoma. The mRNA expression levels in neoplastic tissues compared to the healthy tissues were obtained as the parameters of p-value 2, and gene ranking in the t...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Joe Abdo1, Christopher S. Wichman2, Nicholas E. Dietz1,3, Pawel Ciborowski4, John Fleegel1, Sumeet K. Mittal1,5 and Devendra K. Agrawal1* 1Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, United States 2Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States 3Department of Pathology, CHI Health Creighton University Medical Center, College of Medicine, Omaha, NE, United States 4Department of Pharmacology, University of Nebraska Medical Center, Omaha, NE, United States 5Norton Thoracic Institute, St....
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma. Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment. After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival. “I was surprised at the result,” Meng told The Mesothelioma Center at Asbestos.com. “After taking the drug, the quality o...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This study aimed to explore whether a correlation exists between the incidence and mortality of cancers and normalized internet search volumes on the big data platform, Baidu. We also assessed whether the distribution of people who searched for specific types of cancer differed by gender. Finally, we determined whether there were regional disparities among people who searched the Web for cancer-related information. Methods: Standard Boolean operators were used to choose search terms for each type of cancer. Spearman’s correlation analysis was used to explore correlations among monthly search index values for each can...
Source: Journal of Medical Internet Research - Category: General Medicine Authors: Source Type: research
You're reading 4 Key Ingredients to Avoid in Cosmetics, originally posted on Pick the Brain | Motivation and Self Improvement. If you're enjoying this, please visit our site for more inspirational articles. As you walk down a store’s beauty aisle, it’s easy to choose the most popular brands and products that line the shelves. After all, they are on sale and the labels claim to be organic or all natural. Despite these perks, what consumers fail to realize is that these labels can deceive consumers into believing their items are safe and toxin-free. The truth is the beauty market across the United States has lack...
Source: PickTheBrain | Motivation and Self Improvement - Category: Consumer Health News Authors: Tags: featured health and fitness self improvement beauty pickthebrain toxic Source Type: blogs
We aimed to evaluate the diagnostic utility of PET-CT in differential diagnosis of MPE.Patients with pleural effusion and cancer who underwent PE T-CT were studied. Thoracentesis was performed for all cases.Sudy population consisted of 69 patients with a mean age of 63.55. Definitive diagnosis of MPE was confirmed by cytopathology In 16 cases, effusion was paramalignant. Malignant cells were detected in fluids with no FDG uptake in 13 lung cancer, 3 mesothelioma, 2 breast cancer, 2 colon cancer, 1 ovarian cancer, 1 gastric cancerand 1 endometrium cancer cases. The sensitivity of PET-CT in malignant pleural effusion is foun...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pleural and Mediastinal Malignancies Source Type: research
The National Institutes of Health (NIH) in Bethesda, Maryland, is opening the first mesothelioma clinical trial involving the immunotherapy drug Lynparza (olaparib), a protein inhibitor and targeted therapy already used effectively with breast and ovarian cancers. The phase II clinical trial, for patients previously treated with standard chemotherapy, is designed to gauge the response rate in pleural and peritoneal mesothelioma. Mesothelioma specialist Dr. Raffit Hassan of the National Cancer Institute (NCI) is the senior investigator for the single-center trial, which hopes to enroll at least 40 patients. Earlier research...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Alimta | Asbestosis | Avastin | Biology | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Environmental Health | Gastroschisis Repair | Genetics | Immunotherapy | Mesothelioma | Molecular Biology | Ovarian Cancer | Ovaries | Study | UK Health